Eli Lilly Receives FDA Request for Additional Data on Obesity Pill
Eli Lilly (LLY) has been asked by the FDA to provide additional data on potential liver injury and conduct post-marketing studies for its obesity drug, Foundayo. The FDA also requested a lactation study as part of its safety monitoring. The company stated that no liver damage was observed in late-stage trials and that the approval was based on data from the ATTAIN clinical program.
Tickers: $LLY
Topics: Clinical Trials Drug Safety FDA Foundayo Obesity Pill